Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC III: Treatment of Extracranial Germ Cell Tumours in Children
NCT00274950Phase 3Unknown
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- May 2005
- Primary completion
- May 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 3, open-label trial of carboplatin, etoposide and bleomycin in extracranial germ cell tumor (EGCT) (4 arms), sponsored by Children's Cancer and Leukaemia Group. Primary endpoints: Event-Free Survival and Continuation of treatment. Status: unknown.
02
Drugs
carboplatinetoposidebleomycin
03
Conditions
extracranial germ cell tumor (EGCT)
Beyond the preview
Go deeper on NCT00274950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274950.